Recent studies have shown that proteolysis-targeting chimeras (PROTACs) are a new frontier for therapeutics [39–41], and our data provide a strategy for the RNF113A-targeted degradation of METTL3 in AML. The gene discussed is METTL3; the disease is acute myeloid leukemia.